CL2013001101A1 - Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa. - Google Patents
Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa.Info
- Publication number
- CL2013001101A1 CL2013001101A1 CL2013001101A CL2013001101A CL2013001101A1 CL 2013001101 A1 CL2013001101 A1 CL 2013001101A1 CL 2013001101 A CL2013001101 A CL 2013001101A CL 2013001101 A CL2013001101 A CL 2013001101A CL 2013001101 A1 CL2013001101 A1 CL 2013001101A1
- Authority
- CL
- Chile
- Prior art keywords
- deuterium
- enriched
- compounds
- rasagiline
- parkinson
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
- C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Psychology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40674010P | 2010-10-26 | 2010-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001101A1 true CL2013001101A1 (es) | 2013-09-06 |
Family
ID=45973513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001101A CL2013001101A1 (es) | 2010-10-26 | 2013-04-22 | Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120101168A1 (es) |
| EP (1) | EP2632254A4 (es) |
| JP (1) | JP2014503480A (es) |
| KR (1) | KR20140023872A (es) |
| CN (1) | CN103188933A (es) |
| AU (1) | AU2011320611A1 (es) |
| BR (1) | BR112013010308A2 (es) |
| CA (1) | CA2816104A1 (es) |
| CL (1) | CL2013001101A1 (es) |
| EA (1) | EA201390613A1 (es) |
| IL (1) | IL225852A0 (es) |
| MX (1) | MX2013004598A (es) |
| NZ (1) | NZ610526A (es) |
| SG (2) | SG10201508771TA (es) |
| WO (1) | WO2012058219A2 (es) |
| ZA (1) | ZA201303505B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| AU2007235517B2 (en) * | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
| CN101557706B (zh) * | 2006-12-14 | 2013-08-07 | 泰华制药工业有限公司 | 雷沙吉兰碱结晶固体 |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| EP2451771B1 (en) | 2009-07-09 | 2014-06-18 | Ratiopharm GmbH | Salts of rasagiline and pharmaceutical preparations thereof |
| EP2485722A1 (en) * | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| AU2010341499A1 (en) * | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| JP2013537530A (ja) | 2010-07-27 | 2013-10-03 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトレートの分散物 |
| CN103930100A (zh) | 2011-10-10 | 2014-07-16 | 泰华制药工业有限公司 | R(+)-n-甲基-炔丙基-氨基茚满 |
| CN103874487A (zh) | 2011-10-10 | 2014-06-18 | 泰华制药工业有限公司 | R(+)-n-甲酰-炔丙基-氨基茚满 |
| MX2015002062A (es) | 2012-08-17 | 2015-06-05 | Teva Pharma | Formulaciones parenterales de rasagilina. |
| CN111323524B (zh) * | 2020-04-08 | 2022-04-15 | 重庆华森制药股份有限公司 | 一种炔丙胺及其杂质的检测方法 |
| CN115947675B (zh) * | 2022-12-21 | 2024-05-31 | 博济医药科技股份有限公司 | 一种雷沙吉兰中间体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| AU2005269416B2 (en) * | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| AU2006245349A1 (en) * | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| EP1948248A2 (en) * | 2005-11-06 | 2008-07-30 | Katz-Brull, Rachel | Magnetic resonance imaging and spectroscopy means and methods thereof |
| EP2280929B1 (en) * | 2008-06-02 | 2018-01-31 | Generics [UK] Limited | An improved process for the preparation of rasagiline |
| MX2010013766A (es) * | 2008-06-13 | 2011-03-15 | Teva Pharmaceutical Ind Ltd Star | Rasagilina para modificacion de enfermedad de parkinson. |
| WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US20100286124A1 (en) * | 2009-04-10 | 2010-11-11 | Auspex Pharmaceuticals, Inc. | Prop-2-yn-1-amine inhibitors of monoamine oxidase type b |
| WO2011024156A1 (en) * | 2009-08-31 | 2011-03-03 | Brain Watch Ltd. | Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
-
2011
- 2011-10-25 US US13/281,054 patent/US20120101168A1/en not_active Abandoned
- 2011-10-25 EP EP11836950.3A patent/EP2632254A4/en not_active Withdrawn
- 2011-10-25 KR KR1020137013167A patent/KR20140023872A/ko not_active Application Discontinuation
- 2011-10-25 NZ NZ610526A patent/NZ610526A/en not_active IP Right Cessation
- 2011-10-25 MX MX2013004598A patent/MX2013004598A/es not_active Application Discontinuation
- 2011-10-25 CA CA2816104A patent/CA2816104A1/en not_active Abandoned
- 2011-10-25 AU AU2011320611A patent/AU2011320611A1/en not_active Abandoned
- 2011-10-25 BR BR112013010308A patent/BR112013010308A2/pt not_active IP Right Cessation
- 2011-10-25 WO PCT/US2011/057698 patent/WO2012058219A2/en active Application Filing
- 2011-10-25 SG SG10201508771TA patent/SG10201508771TA/en unknown
- 2011-10-25 EA EA201390613A patent/EA201390613A1/ru unknown
- 2011-10-25 SG SG2013029293A patent/SG189454A1/en unknown
- 2011-10-25 JP JP2013536727A patent/JP2014503480A/ja active Pending
- 2011-10-25 CN CN2011800519198A patent/CN103188933A/zh active Pending
-
2013
- 2013-04-21 IL IL225852A patent/IL225852A0/en unknown
- 2013-04-22 CL CL2013001101A patent/CL2013001101A1/es unknown
- 2013-05-14 ZA ZA2013/03505A patent/ZA201303505B/en unknown
-
2014
- 2014-06-20 US US14/310,321 patent/US20140364506A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013004598A (es) | 2013-07-17 |
| US20120101168A1 (en) | 2012-04-26 |
| EA201390613A1 (ru) | 2013-11-29 |
| WO2012058219A3 (en) | 2012-07-26 |
| ZA201303505B (en) | 2015-08-26 |
| CN103188933A (zh) | 2013-07-03 |
| EP2632254A2 (en) | 2013-09-04 |
| WO2012058219A2 (en) | 2012-05-03 |
| NZ610526A (en) | 2015-10-30 |
| US20140364506A1 (en) | 2014-12-11 |
| SG189454A1 (en) | 2013-05-31 |
| JP2014503480A (ja) | 2014-02-13 |
| KR20140023872A (ko) | 2014-02-27 |
| IL225852A0 (en) | 2013-06-27 |
| CA2816104A1 (en) | 2012-05-03 |
| EP2632254A4 (en) | 2015-08-05 |
| AU2011320611A1 (en) | 2013-06-13 |
| BR112013010308A2 (pt) | 2016-07-05 |
| SG10201508771TA (en) | 2015-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001101A1 (es) | Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa. | |
| ECSP18048718A (es) | Imidazolilimidazoles condensados como compuestos antivirales | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CL2015001699A1 (es) | Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c. | |
| EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| UY35334A (es) | Compuestos y composiciones como degradantes selectivos del receptor de estrógeno | |
| CL2007002572A1 (es) | Compuestos derivados de benzotiazol, moduladores de quinasa; composicion farmaceutica que los contiene; y su uso para el tratamiento de un trastorno mediado por la quinasa c-jun-n-terminal, tales como trastornos autoinmunes, inflamatorios, metabolico | |
| UY33735A (es) | Compuestos antivirales | |
| CO6680663A2 (es) | Composiciones pesticidas producidas de piranosas, composiciones que las contienen y su proceso de obtención | |
| CL2015000946A1 (es) | Compuestos derivados de quinolinilo unidos a fenilo; composicion farmaceutica y su proceso de elaboracion; un metodo para tratar o mejorar un sindrome trastorno, o enfermedad inflamatoria mediada por ror-gamma-t, tal como artritis reumatoide, psoriasis, enfermedad de crohn, entre otras. | |
| CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
| BR112012027509A2 (pt) | composto, processo para a preparação de composto, composição farmacêutica, uso de composto, e, método | |
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| UY32571A (es) | Compuestos derivados de pirazol amida | |
| CL2007002834A1 (es) | Compuestos derivados de pirazina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos relacionados con inflamacion, tales como artritis, intestino inflamado, alergia, | |
| UY35537A (es) | Compuestos de amida sustituida | |
| BRPI1011043B8 (pt) | fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica | |
| CL2013001604A1 (es) | Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis. | |
| CL2014003130A1 (es) | Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune. | |
| ECSP15013883A (es) | Benzamidas | |
| UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) |